WO2000077031A3 - Muc1 ligands - Google Patents

Muc1 ligands Download PDF

Info

Publication number
WO2000077031A3
WO2000077031A3 PCT/CA2000/000711 CA0000711W WO0077031A3 WO 2000077031 A3 WO2000077031 A3 WO 2000077031A3 CA 0000711 W CA0000711 W CA 0000711W WO 0077031 A3 WO0077031 A3 WO 0077031A3
Authority
WO
WIPO (PCT)
Prior art keywords
muc1
ligands
muc1 ligands
ligand
bind
Prior art date
Application number
PCT/CA2000/000711
Other languages
French (fr)
Other versions
WO2000077031A2 (en
Inventor
Jean Gariepy
Shaoxian Yang
Original Assignee
Univ Health Network
Jean Gariepy
Shaoxian Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network, Jean Gariepy, Shaoxian Yang filed Critical Univ Health Network
Priority to AU53822/00A priority Critical patent/AU5382200A/en
Publication of WO2000077031A2 publication Critical patent/WO2000077031A2/en
Publication of WO2000077031A3 publication Critical patent/WO2000077031A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Novel ligands that bind to MUC1 are disclosed. The ligands were isolated using an improved phage display technique using MUC1 tandem repeat as a target. Uses of the ligand to detect, monitor or treat cancer as well as to prepare antibodies is also described.
PCT/CA2000/000711 1999-06-15 2000-06-15 Muc1 ligands WO2000077031A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53822/00A AU5382200A (en) 1999-06-15 2000-06-15 Muc1 ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13926399P 1999-06-15 1999-06-15
US60/139,263 1999-06-15

Publications (2)

Publication Number Publication Date
WO2000077031A2 WO2000077031A2 (en) 2000-12-21
WO2000077031A3 true WO2000077031A3 (en) 2001-04-19

Family

ID=22485831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000711 WO2000077031A2 (en) 1999-06-15 2000-06-15 Muc1 ligands

Country Status (2)

Country Link
AU (1) AU5382200A (en)
WO (1) WO2000077031A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001277854B2 (en) * 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US20020110841A1 (en) 2000-12-22 2002-08-15 KUFE Donald W. Regulation of cell growth by MUC1
US20030092077A1 (en) * 2001-05-04 2003-05-15 Ramarao Chodavarapu S. Human sperm activator peptides
EP2116248A1 (en) * 2001-09-05 2009-11-11 Minerva Biotechnologies Corporation Compositions and Methods of Treatment of Cancer
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
ES2381118T3 (en) * 2004-12-23 2012-05-23 Campina Nederland Holding B.V. Protein hydrolyzate enriched in DPP-IV inhibition peptides and their use
TW200803751A (en) 2005-11-30 2008-01-16 Campina Nederland Holding Bv Use of a protein hydrolysate for enhancing activity of glucagon-like peptide-1
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US10344052B2 (en) * 2013-03-14 2019-07-09 Health Research, Inc. Targeting peptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018534A1 (en) * 1991-04-23 1992-10-29 Antisoma Limited Minimum recognition unit of a pem mucin tandem repeat specific monoclonal antibody
WO1996009411A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
WO1997011715A1 (en) * 1995-09-27 1997-04-03 The Austin Research Institute Mimicking peptides in cancer therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018534A1 (en) * 1991-04-23 1992-10-29 Antisoma Limited Minimum recognition unit of a pem mucin tandem repeat specific monoclonal antibody
WO1996009411A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
WO1997011715A1 (en) * 1995-09-27 1997-04-03 The Austin Research Institute Mimicking peptides in cancer therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APOSTOLOPOULOS V ET AL: "CELLULAR MUCINS: TARGETS FOR IMMUNOTHERAPY", CRITICAL REVIEWS IN IMMUNOLOGY,XX,CRC PRESS, INC, vol. 14, no. 3/04, 1994, pages 293 - 309, XP002071247, ISSN: 1040-8401 *
GARIEPY JEAN ET AL: "Identification of short peptide ligands that bind specifically to the breast tumor-associated MUC1 epitope.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 101 - 102, XP000949494, ISSN: 0197-016X *
LAING P ET AL: "SELECTION OF PEPTIDE LIGANDS FOR THE ANTIMUCIN CORE ANTIBODY C595 USING PHAGE DISPLAY TECHNOLOGY: DEFINITION OF CANDIDATE EPITOPES FOR A CANCER VACCINE", JOURNAL OF CLINICAL PATHOLOGY,GB,LONDON, vol. 48, no. 3, 1995, pages M136 - M141, XP000906851, ISSN: 0021-9746 *
MANOUTCHARIAN KAREN ET AL: "Characterization of cerebrospinal fluid antibody specificities in neurocysticercosis using phage display peptide library.", CLINICAL IMMUNOLOGY (ORLANDO), vol. 91, no. 1, April 1999 (1999-04-01), pages 117 - 121, XP000946486, ISSN: 1521-6616 *

Also Published As

Publication number Publication date
AU5382200A (en) 2001-01-02
WO2000077031A2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
MXPA04004814A (en) Methods for ligand discovery.
WO2001094641A3 (en) Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
WO2002055562A3 (en) Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
WO2001047959A3 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2002097395A3 (en) P-cadherin as a target for anti-cancer therapy
AU2002315157A1 (en) Methods of screening for ligands of target molecules
CA2393629A1 (en) Catalysts for hydrosilylation reactions
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2005016266A3 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
AU3546400A (en) Tandem immuno-assay for cancer
AU2003283839A1 (en) Heteropolyacid and/or its salt supported catalyst, production process of the catalyst and production process of compound using the catalyst
WO2001030964A3 (en) Anti-cancer nucleic acid and protein targets
WO2000077031A3 (en) Muc1 ligands
WO2004087735A3 (en) Proteolytic and covalent antibodies
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
EP0924296A3 (en) Methods and means for inducing apoptosis by interference in RNA processing
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO1999028460A3 (en) Molecules interacting with apoptin
WO1999028461A3 (en) Methods and means for inducing apoptosis by interfering with bip-like proteins
WO2002065133A3 (en) Ligands used for detecting prions
AU2002351374A1 (en) Antibodies to treat cancer
WO2000061551A3 (en) Pyrimidine-2-one derivatives as integrin receptor ligands
WO1999064040A8 (en) Novel polyene macrolide compounds and uses
WO2001053524A3 (en) Cancer associated genes and their products
WO2000040752A3 (en) Cancer associated genes and their products

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP